Today VieCure announced that the United States Patent & Trademark Office has issued VieCure’s patent, U.S. Patent No. 11,798,689 “Generating Customizable Personal Healthcare Treatment Plans”, covering the VieCure platform’s ability to use data and apply computerized algorithms to create healthcare…
eClinicalWorks®, the largest ambulatory cloud EHR, today announced that Integrated Medical Health (IM | Health) — a 22-provider primary care clinic in Wayne, PA — significantly grew its multi-specialty practice using eClinicalWorks EHR and healow patient engagement solutions. IM | Health provides comprehensive…
Talkspace (Nasdaq: TALK), a leading online behavioral health company, announced today the appointment of Nikole Benders-Hadi, MD, as Chief Medical Officer. In this role, Dr. Benders-Hadi will lead Talkspace’s clinical practice, partnering with providers to deliver the highest quality digital mental…
Alphatec Holdings, Inc. (“ATEC”) (NASDAQ: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced that it has commenced a proposed underwritten public offering of $150 million of shares of its common stock. In…
GigXR, Inc., a global provider of holographic healthcare training, announced today its partnership with the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), one of the world’s leading medical schools, to introduce a new gastrointestinal module for…
Lucent Diagnostics, a diagnostics brand of Quanterix Corporation (NASDAQ: QTRX), today announced expansion of its LucentAD product line with the addition of a high accuracy p-Tau 217 blood test for Alzheimer’s disease – LucentAD p-Tau 217. This lab developed test…
Aetna®, a CVS Health® company (NYSE: CVS), announced today that 87 percent of its Medicare Advantage (MA) members are in 2024 Medicare Advantage Prescription Drug (MAPD) plans that are rated 4 stars or higher (out of 5 stars) by the Centers…
Kaiser Permanente issued the following statement from Greg A. Adams, chair and chief executive officer of Kaiser Permanente, as part of the announcement of a settlement agreement with the Department of Managed Health Care (DMHC) over improvements to behavioral health care within…
AbbVie (NYSE: ABBV) today announced that its Phase 2b study evaluating upadacitinib (RINVOQ®) in adults with non-segmental vitiligo (NSV) met the primary endpoint of percent change from baseline in the Facial Vitiligo Area Scoring Index (F-VASI) at week 24 with the 11…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA, Merck’s anti-PD-1 therapy, in…
Pfizer Inc. (NYSE:PFE) today announced that it has amended its supply agreement with the U.S. government for Paxlovid, the first oral antiviral pill approved by the U.S. Food and Drug Administration (FDA) and is updating its Full-Year 2023 Guidance. Paxlovid…
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis (UC). The approved recommended dose…